Wang Angela Yee-Moon, Lai Kar-Neng
University Department of Medicine, Queen Mary Hospital, University of Hong Kong, 102 Pok Fu Lam Road, Hong Kong.
J Am Soc Nephrol. 2008 Sep;19(9):1643-52. doi: 10.1681/ASN.2008010012. Epub 2008 Mar 5.
Mortality among patients with ESRD remains high because of an excessive cardiovascular risk related to a very high incidence of cardiac hypertrophy, cardiomyopathy, heart failure, and coronary artery disease. Identifying serum biomarkers that are useful in profiling cardiovascular risk and enabling stratification of early mortality and cardiovascular risk is an important goal in the treatment of these patients. This review examines current evidence pertaining to the role and utility of two emerging cardiac biomarkers, B-type natriuretic peptide and cardiac troponin T, in patients with ESRD. Together, these data demonstrate how these two cardiac biomarkers may play an adjunctive role to echocardiography in assessing cardiovascular risk and how they may aid in the clinical treatment of these patients.
由于与心脏肥大、心肌病、心力衰竭和冠状动脉疾病的高发病率相关的过度心血管风险，终末期肾病（ESRD）患者的死亡率仍然很高。识别有助于评估心血管风险并实现早期死亡率和心血管风险分层的血清生物标志物是这些患者治疗中的一个重要目标。本综述探讨了两种新兴心脏生物标志物B型利钠肽和心肌肌钙蛋白T在ESRD患者中的作用和效用的现有证据。这些数据共同证明了这两种心脏生物标志物如何在评估心血管风险方面可能发挥辅助超声心动图的作用，以及它们如何有助于这些患者的临床治疗。
